NVTA - Invitae Corporation : US

แหล่งรวบรวมข้อมูลของหุ้นประเทศ All for one, one for global
(ช่วงทดลองเปิดตัว สมาชิกและทุกท่านสามารถเข้าได้ตลอด)
Post Reply
PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Nov 25, 2020 11:05 pm

บริษัทนี้ตรวจdna,genetic กับผู้บริโภคทั่วไป ลองเข้าไปเล่นในwebsiteดูได้ครับ https://www.invitae.com/en

กองarkถือหุ้นใหญ่อยู่คาดว่าอนาคตคงโตได้อีกเยอะ คนน่าจะหันมาตรวจกันมากขึ้นเพื่อรู้ว่าเรามีความเสี่ยงอะไรบ้างครับ



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Fri Dec 11, 2020 10:01 am




PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Fri Dec 11, 2020 10:01 am


SAN FRANCISCO, Dec. 9, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and cancer screening for patients and their families. The studies, which will be presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), add to the evidence supporting universal access to genetic information for all breast cancer patients.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Tue Dec 29, 2020 10:59 am




User avatar
mr.bullish
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 157
Joined: Wed Aug 16, 2017 8:30 am

Re: NVTA - Invitae Corporation : US

Posts by mr.bullish » Tue Dec 29, 2020 4:14 pm

top 10 holdings ของ ARKG ครับ ที่ Cathie Wood คาดว่าจะเป็นปีแห่ง gene editing และ therapeutic



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Tue Dec 29, 2020 9:23 pm

SAN FRANCISCO, Dec. 29, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. Following the company presentation, management will participate in a virtual breakout session at 11:10 a.m. Eastern/8:10 a.m. Pacific.

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
More
The 2021 J.P. Morgan Healthcare Conference is being held virtually via webinar. A live webcast of both the presentation and the breakout session may be accessed at the following direct link or by visiting the investors section of the company's website at ir.invitae.com.

Public listeners can access an audio and slide recording of the session, which will be available shortly after the conclusion of the presentation and breakout session on the investors section of the company's website at ir.invitae.com.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Mon Jan 11, 2021 7:36 pm

January 11, 2021
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume

-- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific --
SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong growth in volume and revenue, signaling continued momentum into 2021.

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
"We are very pleased by the acceleration of our business in 2020, particularly in light of the impact of the COVID-19 pandemic on the healthcare system throughout the year," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "Our results underscore the strength of our customer relationships, our continued ability to execute and the benefits of the investments we've made in expanding our menu, services and platform. The growth in testing during this time of unrelenting stress on the healthcare system further demonstrates the expanding value genetic information is providing patients as they and their physicians face health challenges and decisions."

Preliminary, unaudited financial results and other metrics for 2020

Generated revenue of more than $278 million in 2020, an approximate 28% increase from $217 million in 2019
Reported billable volume of more than 655,000 in 2020, an approximate 40% increase from billable volume of 469,000 in 2019
Announced year-end 2020 cash, cash equivalents, restricted cash and marketable securities of more than $360 million as of December 31, 2020
Outlook for 2021
Looking ahead to 2021 and factoring in the continued impact associated with the COVID-19 pandemic, Invitae reiterates its stated outlook for revenue growth targets of 50% - 60% annual growth over the next few years consistent with its view at the time of the announcement of the ArcherDX acquisition. Invitae anticipates generating revenue in excess of $450 million in 2021.

"We are confident we will continue growing rapidly in 2021, even as we navigate the continued pressure the pandemic is placing on clinicians," said Dr. George. "Our momentum coming out of 2020 and the underlying strength and breadth of our platform enable us to recognize and overcome these challenges while continuing to drive the acceleration of the adoption of genetics in mainstream medicine as the new standard of care."

Invitae has not completed preparation of its financial statements for the fourth quarter or full year 2020. The preliminary, unaudited results presented in this press release for the year ended December 31, 2020 are based on current expectations and are subject to adjustment. Actual results may differ materially from those disclosed in this press release. Invitae will report its full financial results and other metrics during its fourth quarter and year-end 2020 conference call in February.

Invitae's Presentation at 39th Annual J.P. Morgan Healthcare Conference
Invitae will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. Following the company presentation, management will participate in a breakout session at 11:10 a.m. Eastern/8:10 a.m. Pacific. The 2021 J.P. Morgan Healthcare Conference is being held virtually via webinar. A live webcast of both the presentation and the breakout session may be accessed at the following direct link or by visiting the investors section of the company's website at ir.invitae.com. Public listeners can access an audio and slide recording of the session, which will be available shortly after the conclusion of the presentation and breakout session on the investors section of the company's website at ir.invitae.com.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Jan 13, 2021 10:47 pm

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate HiFi sequencing to expand Invitae’s whole genome testing capabilities.

“Whole genome sequencing has the ability to significantly improve diagnosis for a wide range of diseases and guide healthcare throughout life. This collaboration is aimed at developing the technology to make it affordable and accessible to all patients who can benefit from in-depth, full genome information," said Sean George, co-founder and Chief Executive Officer of Invitae. “Our work with PacBio to date has demonstrated the increased diagnostic yield and clinical utility of using information from high-quality, long-read genomes to guide patient care. We believe this world-class sequencing technology combined with our clinical capabilities will uniquely position us to deliver those benefits cost effectively at scale. We look forward to working with the PacBio team to develop a new generation of innovative whole genome-based offerings.”

Identifying the many underlying genetic influences on human health is becoming increasingly critical to overall clinical care and prognosis and whole genome sequencing offers the most comprehensive view of medically relevant variations. As whole genome sequencing continues to grow into a preferred method for genetic testing, it is expected by the Global Alliance for Genomics and Health that by 2025 as many as sixty million genomes will be sequenced. With the development of a new sequencing platform, Invitae and PacBio aim to enable a new class of cost-effective assays that could be used to accelerate the accessibility of a more comprehensive whole genome sequencing approach in areas including carrier screening, immune system response, and other heritable diseases.

“Invitae is a leader in medical genetic testing and has driven innovation in this area for more than a decade. We are excited to join forces to develop and implement this new platform which is built on our shared vision that broad access to whole genome sequencing in the clinic has the power to improve diagnosis and access to precision therapies,” said Christian Henry, President and Chief Executive Officer of Pacific Biosciences. “Building on the proven performance of our HiFi sequencing, we believe that this new system will ultimately enable us to deliver the most clinically relevant whole genome at substantially less than $1,000 which we believe is a critical price threshold needed to expand adoption in routine medical care.”

PacBio HiFi sequencing combines the high accuracy of Sanger sequencing (>99.9%) with long reads up to 25 kb. Together, the length and accuracy of HiFi reads provide excellent detection of variants from single nucleotide changes to large structural variants, even in hard-to-sequence regions of the genome.

Through the collaboration, both companies will commit significant resources to support development of a production-scale sequencing platform designed with the capacity to process clinical whole genomes at scale. Those resources are expected to include talent, technology and collaborative oversight, and Invitae will also invest capital to support development throughout the multi-year effort.



User avatar
mr.bullish
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 157
Joined: Wed Aug 16, 2017 8:30 am

Re: NVTA - Invitae Corporation : US

Posts by mr.bullish » Sun Jan 17, 2021 7:46 pm

phpBB [video]


กองนี้ fund of fund อธิบายภาษาไทยเข้าใจง่ายดีครับ
มี invitae ด้วย



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Jan 20, 2021 10:36 pm

Update Major shareholder



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Fri Jan 22, 2021 10:28 am

SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 1,165,048 shares of its common stock at the public offering price, less underwriting discounts and commissions.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Jan 27, 2021 1:54 pm




PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Thu Feb 18, 2021 10:26 am

Full Year and Fourth Quarter 2020 Financial Results

Generated revenue of $279.6 million in 2020, including $100.4 million in the fourth quarter.

Reported 659,000 in billable test volume in 2020, including 238,000 in the fourth quarter.

Reported average cost per unit of $299 during 2020, and $284 in the fourth quarter. Non-GAAP average cost per unit was $261 for the year and $227 in the fourth quarter.

Reported gross profit of $81.3 million in 2020, including $32.2 million in the fourth quarter. Non-GAAP gross profit was $106.8 million in 2020, and $45.5 million in the fourth quarter.

Total operating expense, excluding cost of revenue, for the full year 2020 was $733.5 million. Operating expense for the fourth quarter of 2020 was $363.7 million. Non-GAAP operating expense was $456.1 million for the full year 2020 and $145.9 million in the fourth quarter.

For the full year 2020, net loss was $608.9 million, or a $4.52 net loss per share. For the fourth quarter of 2020, Invitae reported a net loss of $241.0 million, or a $1.34 net loss per share. Non-GAAP net loss was $373.9 million, or a $2.78 non-GAAP net loss per share in 2020. For the fourth quarter of 2020, Invitae reported a non-GAAP net loss of $113.1 million, or a $0.63 non-GAAP net loss per share.

At December 31, 2020, cash, cash equivalents, restricted cash and marketable securities totaled $360.7 million. Net decrease in cash, cash equivalents and restricted cash was $26.1 million in 2020 and a net increase of $18.4 million for the fourth quarter. Cash burn was $441.1 million in the fourth quarter of 2020, which includes $352.7 million for cash paid for acquisitions, primarily of ArcherDX, and $13.6 million for cash paid for acquisition related expenses. Cash burn for the quarter would have been approximately $74.8 million, which includes $29.1 million of burn by ArcherDX in the fourth quarter, without the acquisition and acquisition-related costs.

Subsequent to the close of the fourth quarter on January 26, 2021, the company announced the sale of approximately 8.9 million shares of its common stock at a price of $51.50 per share, resulting in net proceeds, after underwriting discounts and commissions and offering expenses, of more than $434 million.

Looking ahead to 2021 and factoring in the continued impact associated with the COVID-19 pandemic, Invitae reiterates its stated outlook for revenue growth targets of 50% - 60% annual growth over the next few years consistent with its view at the time of the announcement of the ArcherDX acquisition. Invitae anticipates generating revenue in excess of $450 million in 2021.

This press release contains non-GAAP financial measures. Investors are encouraged to review the non-GAAP reconciliations provided in the tables below.

Full Year Corporate Highlights
Throughout 2020 and into early 2021, the company has maintained its focus on continued development of its menu, services and platform:

Menu

Services

Platform



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Sat Feb 20, 2021 3:58 pm




PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Tue Feb 23, 2021 7:47 pm

Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians

-- Clinicians can now share test results reports with patients directly, reducing delays and need for in-person visits --
SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients in an intuitive, enjoyable and telemedicine-friendly conversation through receiving and understanding genetic test results and possible next steps, including scheduling a call with a genetics counselor.

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
"While the pandemic brought new urgency to the need for telemedicine-friendly patient tools, we've known for a long time that Gia can make the genetic testing process easier and more accessible for both patients and clinicians," said Moran Snir, co-developer of Gia and head of experience platform at Invitae. "By adding support for returning results to Gia's capabilities, we can help reduce delays caused by wait lists for in-person appointments and hours of travel to appointments, while freeing up genetic counselors to provide intensive counseling and support for patients who need it. These kinds of tools are essential for helping more clinicians incorporate genetics into routine clinical care for their patients."

Gia provides an industry-leading patient genetics chatbot experience. The chatbot is integrated into software that supports clinical workflow throughout the genetic testing process, from pretest education to family history gathering and ordering support and continuing through post-test education. Coupled with Invitae's full suite of software solutions that provide comprehensive workflow support, a wide variety of clinicians such as obstetrician/gynecologists, oncologists and genetic counselors can use Gia to help them integrate routine genetic testing into patient care. Importantly, chatbot technology also helps clinicians overcome disparities in access to genetic information by addressing language and socioeconomic barriers.

Gia, which stands for "genetic information assistant," was designed in partnership with genetic counselors to help streamline communication between patients and clinicians. Launched in 2017 and deployed by major academic health systems, the platform has helped more than 100,000 patients with pretest education and intake and post-test counseling. Gia is HIPAA-compliant and has a 92% satisfaction rate among patients. Gia is available to clinicians in the United States.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Mar 03, 2021 9:12 pm

- New program expected to improve access to genetic testing for activated PI3K delta syndrome (APDS), an ultra-rare immunodeficiency disease

- Program has potential to advance clinical research in APDS as a result of earlier diagnosis

LEIDEN, The Netherlands, March 2, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, in collaboration with Invitae Corporation (NYSE: NVTA, "Invitae"), a leading medical genetics company, announces the launch of a sponsored genetic testing program, navigateAPDS, designed to assist clinicians in identifying patients and their family members with activated PI3K delta syndrome (APDS), which may lead to earlier diagnosis.

APDS is an ultra-rare primary immunodeficiency disease caused by a genetic mutation affects approximately 1-2 people per million. Patients are often misdiagnosed with other immunodeficiencies or autoimmune disorders and often have a protracted course to obtain a correct diagnosis. A definitive diagnosis can be made only by a genetic test. Current treatment is generally limited to supportive therapies such as antibiotics and the use of immunoglobulin replacement therapy. There is no approved therapy for the treatment of APDS, however, clinical trials are currently ongoing, including Pharming's pivotal-stage development program for leniolisib, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor, under development by Novartis and Pharming to treat patients with APDS.

Pharming's support of the program will facilitate genetic testing and counselling for eligible individuals in the United States and Canada at no charge. NavigateAPDS will use the Invitae Primary Immunodeficiency Panel (PI), which analyzes up to 407 genes that are associated with inherited disorders of the immune system. In addition to providing genetic testing to individuals who may present with a clinical picture known to be associated with APDS, navigateAPDS will offer pre-test and post-test genetic counseling through a third party, and all blood relatives of patients found to have a P/LP variant for APDS are qualified to be tested through the program. By offering access to the full PI panel, physicians and patients are more likely to identify the underlying cause and potential diagnosis without the need for additional expanded patient testing.

Sijmen de Vries, Chief Executive Officer commented:

"Our partnership with Invitae is an important step towards simplifying access to testing, which may allow for an expedited and accurate diagnosis for patients suffering from a primary immunodeficiency such as APDS. Earlier diagnosis can favorably impact disease management and could have a positive effect on long-term outcomes and patients' quality of life. The program is also a key component in advancing clinical research by identifying the underlying causes of APDS, which will help us better understand these patients' potential to respond to investigational precision medicines."

Robert Nussbaum, M.D., Chief Medical Officer of Invitae commented:

"Genetic information is a powerful tool that can improve outcomes for patients and their families, both by supporting more rapid diagnosis of ultra-rare diseases such as APDS and also by enabling access to clinical trials. Partnerships like our work with Pharming may enable the clinical trials necessary to develop precision therapies in areas of significant unmet need."



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Mon Apr 05, 2021 2:58 pm

SoftBank Group Corp. plans to lead an investment of about $1.2 billion into the genetic-testing company Invitae Corp., with an announcement planned for Monday, Dow Jones reported.

The investment will be in the form of convertible debt and is aimed at helping Invitae expand the use of its platform, the publication said. The deal is part of the Japanese company’s effort to put more money into public companies.

SoftBank founder Masayoshi Son has been increasing investments in public traded companies as he sells off certain assets. The Japanese billionaire had previously set up a $100 billion Vision Fund to invest in private startups.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Mon Apr 05, 2021 9:30 pm

PK-TYW wrote:
Mon Apr 05, 2021 2:58 pm
SoftBank Group Corp. plans to lead an investment of about $1.2 billion into the genetic-testing company Invitae Corp., with an announcement planned for Monday, Dow Jones reported.

The investment will be in the form of convertible debt and is aimed at helping Invitae expand the use of its platform, the publication said. The deal is part of the Japanese company’s effort to put more money into public companies.

SoftBank founder Masayoshi Son has been increasing investments in public traded companies as he sells off certain assets. The Japanese billionaire had previously set up a $100 billion Vision Fund to invest in private startups.
Softbank Convertible bondราคาใช้สิทธิ43.18$

Under the terms of the investment, the participating investors, including SB Management, will purchase a total aggregate principal amount of $1.15 billion in Convertible Senior Notes due 2028 (the "Notes"). The Notes will have an initial conversion price of $43.18 per share of the Company's common stock, subject to customary anti-dilution and other adjustments. The initial conversion price of $43.18 represents a 20% premium to the Company's average 5-day trailing volume-weighted average price as of April 1, 2021. The Notes will mature on April 1, 2028, unless earlier converted, redeemed or repurchased. The Notes will bear 1.5% interest per year. Upon conversion, the Company will have the right to elect settlement in cash, shares, or any combination thereof in its sole discretion.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Thu Apr 15, 2021 10:15 pm




PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Tue May 25, 2021 6:39 pm




PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 2208
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Tue Jun 08, 2021 6:39 am




Post Reply